However, recent evidence of low primaquine dosage triggering severe anaemia in an A– type individual (a genotype commonly considered very mildly deficient) [72], and findings from extensive DNA sequencing identifying a greater diversity of G6PD mutations than previously acknowledged [70],[73], calls for caution when using primaquine in these areas of high G6PDd prevalence, in spite of the relatively mild nature of primaquine sensitivity of the A− variants, as determined in otherwise healthy adults (rather than in children with malaria). This evidence concerns the gene G6PD and anemia.